Literature DB >> 1914508

Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells.

T L Knisely1, P A Bleicher, C A Vibbard, R D Granstein.   

Abstract

Aqueous humor contains transforming growth factor-beta (TGF-beta) and other inhibitory factors for cellular proliferation. In the present study we investigated the possibility that these factors are produced locally by cells found within the iris and ciliary body. Iris and ciliary body (I/CB) cells or whole tissue explants from C57BL/6 mice produced soluble factors which inhibited both murine thymocyte and mink lung epithelial cell proliferation. Indomethacin partially blocked inhibition of thymocyte proliferation, but did not affect inhibition of Mv1 Lu proliferation. The inhibitory activity of culture supernatants was not blocked by neutralizing antibodies to TGF-beta 1 or TGF-beta 2. However, following acid activation of culture supernatants from both I/CB and corneal tissue, increased inhibitory activity consistent with activation of latent TGB-beta was detected. Antibody neutralization experiments demonstrated that this increase in activity was due primarily to TGF-beta 2 for I/CB tissue. Polymerase chain reaction (PCR) analysis of cDNA generated from I/CB tissue mRNA showed prominent fragments representing both TGF-beta 1 and TGF-beta 2 mRNA. Corneal tissue, however, showed a prominent fragment for TGF-beta 1 mRNA, but either no band or a barely detectable fragment for TGF-beta 2 mRNA. Therefore, it remains uncertain whether TGF-beta 2 mRNA is produced by the cornea in this strain. Overall, these results demonstrated that three distinct categories of substances inhibitory to proliferation may be locally produced by resident iris and ciliary body cells: 1) indomethacin sensitive products, 2) TGF-beta 2 in latent form, and 3) factors not blocked by indomethacin or anti-TGF-beta neutralizing antibodies. Products generated by these tissues may have important regulatory properties in the development of immune responses to antigens introduced into the anterior chamber.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914508     DOI: 10.3109/02713689109013870

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  13 in total

1.  Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction.

Authors:  M Ueta; M-N Kweon; Y Sano; C Sotozono; J Yamada; N Koizumi; H Kiyono; S Kinoshita
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 2.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 4.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

5.  Inhibition of fibroblast proliferation by human iris pigment epithelial cells in vitro: preliminary results.

Authors:  Z J Fan; H R Wei; A Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-01       Impact factor: 3.117

6.  Lens-specific expression of transforming growth factor beta1 in transgenic mice causes anterior subcapsular cataracts.

Authors:  Y Srinivasan; F J Lovicu; P A Overbeek
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

Review 7.  Matricellular protein thrombospondins: influence on ocular angiogenesis, wound healing and immuneregulation.

Authors:  Sharmila Masli; Nader Sheibani; Claus Cursiefen; James Zieske
Journal:  Curr Eye Res       Date:  2014-02-21       Impact factor: 2.424

8.  An antimicrobial effect associated with rabbit primary aqueous humour.

Authors:  J P Diamond; J P Leeming; A D Smart; P Duffus; A J Hedges; D L Easty
Journal:  Br J Ophthalmol       Date:  1994-02       Impact factor: 4.638

9.  Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.

Authors:  Qiuhong Li; Rehae Miller; Ping-Yang Han; Jijing Pang; Astra Dinculescu; Vince Chiodo; William W Hauswirth
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

10.  Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.

Authors:  Wensheng Li; Fansheng Kong; Xia Li; Xufeng Dai; Xiaoqiang Liu; Qinxiang Zheng; Ronghan Wu; Xiangtian Zhou; Fan Lü; Bo Chang; Qiuhong Li; William W Hauswirth; Jia Qu; Ji-Jing Pang
Journal:  Mol Vis       Date:  2009-02-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.